Biora Therapeutics, Inc. (NASDAQ:BIORQ) — Stock Price
Biora Therapeutics, Inc. (NASDAQ:BIORQ) is currently trading at $0.22 USD, up 0.00% today. This page tracks Biora Therapeutics, Inc.'s live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Biora Therapeutics, Inc. stock valuation.
Biora Therapeutics, Inc. (BIORQ) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Biora Therapeutics, Inc.'s daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Biora Therapeutics, Inc. Income Statement — Revenue, Profit & Earnings by Year
Biora Therapeutics, Inc.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Total Revenue | $4.00K | $305.00K | $1.25 Million | $74.31 Million | $143.99 Million |
| Cost of Revenue | — | — | $0.00 | $93.43 Million | $100.49 Million |
| Gross Profit | $4.00K | $305.00K | $1.25 Million | $-19.12 Million | $43.49 Million |
| Research & Development | $29.84 Million | $24.05 Million | $45.78 Million | $47.74 Million | $63.40 Million |
| SG&A | $37.31 Million | $38.04 Million | $68.54 Million | $75.44 Million | $61.32 Million |
| Total Operating Expenses | $67.15 Million | $62.09 Million | $119.08 Million | $176.07 Million | $183.61 Million |
| Operating Income | $-67.14 Million | $-61.78 Million | $-117.84 Million | $-107.62 Million | $-140.12 Million |
| EBITDA | $-114.05 Million | $-37.35 Million | $-164.57 Million | $-106.18 Million | $-135.44 Million |
| EBIT | $-114.61 Million | $-38.26 Million | $-166.00 Million | $-107.62 Million | $-140.04 Million |
| Interest Expense | $9.81 Million | $10.99 Million | $12.64 Million | $9.91 Million | $9.20 Million |
| Income Before Tax | $-124.42 Million | $-49.25 Million | $-178.64 Million | $-142.62 Million | $-148.74 Million |
| Income Tax Expense | $-90.00K | $-420.00K | $-119.00K | $-37.53 Million | $-706.00K |
| Net Income | $-124.11 Million | $-38.16 Million | $-178.52 Million | $-192.53 Million | $-148.04 Million |
Biora Therapeutics, Inc. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Biora Therapeutics, Inc.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Total Assets | $31.21 Million | $53.52 Million | $108.84 Million | $154.44 Million | $101.73 Million |
| Total Current Assets | $19.07 Million | $38.12 Million | $98.43 Million | $126.34 Million | $74.65 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $830.00K | $828.00K | $653.00K | $6.63 Million | $22.82 Million |
| Inventory | — | — | $2.15 Million | $12.22 Million | $10.94 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | $6.07 Million | $6.07 Million | $6.07 Million | $6.22 Million | $6.22 Million |
| Total Liabilities | $132.64 Million | $155.81 Million | $193.81 Million | $261.43 Million | $185.60 Million |
| Total Current Liabilities | $62.97 Million | $23.30 Million | $61.61 Million | $72.67 Million | $100.34 Million |
| Long-term Debt | $43.74 Million | $127.81 Million | $126.39 Million | — | — |
| Net Debt | $32.22 Million | $98.82 Million | $38.01 Million | $70.23 Million | $40.33 Million |
| Total Stockholder Equity | $-101.42 Million | $-102.29 Million | $-84.98 Million | $-106.99 Million | $-83.87 Million |
| Retained Earnings | $-950.96 Million | $-826.84 Million | $-788.69 Million | $-541.27 Million | $-348.48 Million |
Biora Therapeutics, Inc. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Biora Therapeutics, Inc. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-48.50 Million | $-64.42 Million | $-167.49 Million | $-165.74 Million | $-106.12 Million |
| Capital Expenditures | $103.00K | $792.00K | $855.00K | $4.94 Million | $3.73 Million |
| Free Cash Flow | $-48.60 Million | $-65.21 Million | $-168.34 Million | $-170.69 Million | $-109.85 Million |
| Investing Cash Flow | $2.44 Million | $-792.00K | $-1.24 Million | $-4.94 Million | $16.52 Million |
| Financing Cash Flow | $30.78 Million | $7.30 Million | $165.05 Million | $229.72 Million | $73.64 Million |
| Dividends Paid | — | — | — | — | $4.50 Million |
| Stock-Based Compensation | $16.48 Million | $7.80 Million | $11.96 Million | $8.24 Million | $2.38 Million |
| Depreciation | $555.00K | $907.00K | $1.44 Million | $1.44 Million | $6.35 Million |
| Change in Cash | $-15.28 Million | $-57.91 Million | $-3.68 Million | $59.03 Million | $-15.96 Million |
Biora Therapeutics, Inc. Earnings History — EPS Actual vs. Analyst Estimates
Track Biora Therapeutics, Inc.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 14, 2024 | -5.04 | -3.85 | -30.91% |
| Aug 12, 2024 | -0.40 | -4.50 | +91.11% |
| May 15, 2024 | -1.40 | -4.50 | +68.89% |
| Mar 27, 2024 | -6.20 | -5.95 | -4.20% |
| Nov 13, 2023 | -48.90 | -9.25 | -428.65% |
| Aug 14, 2023 | -14.70 | -16.00 | +8.13% |
| May 15, 2023 | -15.90 | -17.50 | +9.14% |
| Nov 14, 2022 | -7.50 | -18.75 | +60.00% |